These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38359970)
1. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications. Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970 [TBL] [Abstract][Full Text] [Related]
2. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Davies A; Zoubeidi A; Selth LA Endocr Relat Cancer; 2020 Feb; 27(2):R35-R50. PubMed ID: 31804971 [TBL] [Abstract][Full Text] [Related]
3. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903 [TBL] [Abstract][Full Text] [Related]
4. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Berchuck JE; Baca SC; McClure HM; Korthauer K; Tsai HK; Nuzzo PV; Kelleher KM; He M; Steinharter JA; Zacharia S; Spisak S; Seo JH; Conteduca V; Elemento O; Auh J; Sigouros M; Corey E; Hirsch MS; Taplin ME; Choueiri TK; Pomerantz MM; Beltran H; Freedman ML Clin Cancer Res; 2022 Mar; 28(5):928-938. PubMed ID: 34907080 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Yamada Y; Beltran H Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737 [TBL] [Abstract][Full Text] [Related]
6. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695 [TBL] [Abstract][Full Text] [Related]
7. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057 [TBL] [Abstract][Full Text] [Related]
8. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741 [TBL] [Abstract][Full Text] [Related]
9. Treatment-induced neuroendocrine prostate cancer and Wishahi M World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339 [TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer. Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089 [No Abstract] [Full Text] [Related]
11. Molecular events in neuroendocrine prostate cancer development. Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of neuroendocrine prostate cancer. Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487 [TBL] [Abstract][Full Text] [Related]
13. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368 [TBL] [Abstract][Full Text] [Related]
14. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568 [TBL] [Abstract][Full Text] [Related]
15. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of neuroendocrine prostate cancer. de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302 [TBL] [Abstract][Full Text] [Related]